查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
基因组生物标誌物的全球市场-2022-2029
市场调查报告书
商品编码
1129276

基因组生物标誌物的全球市场-2022-2029

Global Genomic Biomarker Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

政府当局对医疗保健行业的投资不断增长，预计将推动市场增长。

根据医疗保险和医疗补助服务中心 (CMS) 的估计，从 2018 年到 2027 年，美国国家医疗保健支出将以年均 5.5% 的速度增长，届时将达到约 6 万亿美元。预计。此外，2020 年 5 月，开发分子诊断技术的德国 Qiagen 公司宣布引入最先进的技术，用于各种类型的癌症的基因组分析。最先进的 QIAseq pan-cancer multimodal panel 发现并富集了 600 多种 DNA 和 RNA 生物标誌物，用于评估肿瘤突变负荷和微卫星不稳定性状态，只需输入一个样本即可。因此，从上述陈述来看，预计市场将在预测期内受到驱动。

限制

基因组生物标誌物的高成本、严格的政府法规以及仅基于遗传生物标誌物的诊断方法的不可靠性。这些是预计在预测期内阻碍市场的一些因素。

行业分析

基因组生物标誌物市场提供基于各种行业因素的市场深入分析，包括供应链分析、定价分析等。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。 SARS-CoV-2具有冠状病毒家族的共同特性，结构特征和进入机制已经阐明。另一方面，快速诱变会导致形成具有不同繁殖率和传染性的新菌株，从而影响疾病的性质和严重程度。 COVID-19 的强度、结果和易感性都被认为受宿主相关因素的影响。生物信息学可用于预测刺突蛋白突变对该菌株感染细胞和粘附 ACE2 受体能力的影响。

此外，SARS-CoV-2 靶向多种转录因子和肿瘤抑制基因，并可能影响许多宿主基因的表达和细胞信号传导。它还可以利用内源性 miRNA 及其病毒 RNA 来抑制宿主细胞中的 RNA 表达。某些人类 miRNA 已被证明与病毒 RNA 的各种编码和非编码区相关以形成双链体。此外，参与病毒进入和復制、分子损伤反应和炎症途径的人类基因多态性可能会影响疾病的预后和病程。基因本体分析表明，这些多态基因编码的蛋白质与防御反应的控制密切相关。因此，病毒宿主相关的遗传和表观遗传生物标誌物可能有助于预测疾病进展和治疗效果。

另一方面，大流行会破坏供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上述描述来看，市场受到了影响，但预计随着经济活动的恢復，市场将急剧回升。

此报告提供对大约 45 多个市场数据表、40 多个数字和 200 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 政府当局对医疗保健行业的投资不断增加，预计将推动市场增长。
    • 限制因素
      • 基因组生物标誌物的高成本预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格波动
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 预测性生物标誌物
  • 预后生物标誌物

第 8 章通过验证

  • 分析验证
  • 临床验证
  • 临床实用性
  • 其他

第 9 章适应症

  • 肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 肾病
  • 其他

第 10 章，最终用户

  • 医院
  • 诊断中心
  • 研究所
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 13 章公司简介

  • Thermo Fisher Scientific
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • QIAGEN
  • Eurofins Scientific
  • Exact Sciences
  • Sema4
  • Creative Diagnostics
  • Centogene N.V.
  • Quanterix

第 14 章全球基因组生物标誌物市场-DataM

简介目录
Product Code: DMOT5830

Market Overview

Genomic Biomarker Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15% during the forecast period (2022-2029).

Genomic biomarkers are signs that assess for clinical diagnosis based on gene expression, gene mutation, gene regulation, and other gene features. Neurological, oncological, and cardiovascular illnesses can all be detected using genomic biomarkers. Genomic biomarkers aid in the early diagnosis of disease, tracking disease progression and assessing the biological response to treatment or therapy. Genomic biomarkers can be utilized as a diagnostic indicator on their own or in conjunction with other biomarkers such as protein biomarkers. mRNA, miRNA, cell-free DNA, long coding RNA, and other genomic biomarkers are used in clinical diagnosis.

Market Dynamics

The growing investment by government authorities in the healthcare industry is expected to drive market growth.

The Centers for Medicare & Medicaid Services (CMS) estimates that national health spending in the United States increased at an average rate of 5.5 percent per year from 2018 to 2027 and is projected to reach around USD 6.0 trillion by that time. Moreover, in May 2020, Qiagen, a German company that develops molecular diagnostics technology, announced the introduction of cutting-edge technologies for genomic analysis in various cancer kinds. The cutting-edge QIAseq pan-cancer multimodal panel with just one sample input can discover and enrich more than 600 DNA and RNA biomarkers for evaluating tumor mutational load and microsatellite instability status. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs of the genomic biomarkers, stringent government restrictions, and diagnostic method based solely on genetic biomarkers is less reliable. These are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The genomic biomarker market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The structural characteristics and entrance mechanism of SARS-CoV-2 are clarified due to the shared characteristics of the coronavirus family. Rapid mutagenesis, on the other hand, causes the formation of novel strains that may have various rates of reproduction or infectiousness and may affect the nature and severity of the illness. The intensity and results of COVID-19 and the susceptibility to infection may all be influenced by host-related factors. The impact of spike protein mutations on the strain's ability to infect cells and attach to the ACE2 receptor can be predicted using bioinformatics.

Additionally, SARS-CoV-2 may target several transcription factors and tumor suppressor genes, impacting the expression of many host genes and cell signaling. By using endogenous miRNA and its viral RNA, the virus may also impede RNA expression in host cells. It is revealed that certain human miRNA may associate with various coding and non-coding regions of viral RNA to produce duplexes. Polymorphisms may also influence the prognosis and course of a disease in human genes involved in viral entry and replication, as well as in molecular damage response and inflammatory pathways. Proteins encoded by these polymorphic genes are highly related to the regulation of the defense response, according to a gene ontology analysis. Genetic and epigenetic biomarkers connected to the virus and host may therefore aid in predicting the progression of the disease and the effectiveness of treatment.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Predictive Biomarkers segment is expected to hold the largest market share in genomic biomarker market

The predictive biomarkers segment is expected to dominate in 2021. The segment benefits because predictive biomarkers are baseline or pretreatment data that reveal whether patients are more or least likely to benefit from a certain treatment. A predictive biomarker is frequently chosen as a companion predictive biomarker in developing a specific therapeutic medication. As a typical oncology example, a biomarker that detects overexpression of the growth factor protein Her-2, which transmits growth signals to breast cancer cells, maybe a predictive biomarker for the administration of trastuzumab (Herceptin). This drug inhibits the effects of Her-2 on breast cancer patients. Therefore, it has increased the demand for predictive biomarkers. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global genomic biomarker market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and cardiovascular disease, advancements in the genomic biomarker, increasing adoption of genomic biomarkers in the early diagnosis of diseases, product launches by the key market players, and regulatory approvals in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of genomic biomarkers in the early diagnosis of diseases.

Moreover, Clinical genomics delivery in everyday healthcare has been completed under Color Genomics' US program, the company announced in January 2020 in collaboration with NorthShore University HealthSystem. Additionally, the business supported Sanford's Imagenetics genomes program, which will improve clinical judgment. This project is also to blame for the region's widespread use of genetic biomarkers. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the genomic biomarker market are Thermo Fisher Scientific,Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., QIAGEN, Eurofins Scientific, Exact Sciences, Sema4, Creative Diagnostics, Centogene N.V., Quanterix.

Bio-Rad Laboratories, Inc.:

Overview:

Bio-Rad Laboratories, Inc. is an American company that continues to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster results. Bio-Rad's life science products include instruments, software, consumables, reagents, and content for cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education. These products are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as antibodies, proteins, nucleic acids, cells, and bacteria. Moreover, Bio-Rad's diagnostic products and systems use various technologies and provide clinical information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. These products support diagnosing, monitoring, and treating diseases and other medical conditions.

Product Portfolio:

CFX Real-Time PCR Detection System: Powerful and flexible instruments with 2-5 color multiplexing to deliver sensitive, reliable detection of both single and multiplex real-time PCR reactions. High-throughput CFX Automation System can screen up to 84 plates in 24 hours.

The global genomic biomarker market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing investment by government authorities in the healthcare industry is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs of the genomic biomarkers are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Predictive Biomarkers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prognostic Biomarkers

8. By Validation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 8.1.2. Market Attractiveness Index, By Validation Segment
  • 8.2. Analytical Validation*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinical Validation
  • 8.4. Clinical Utility
  • 8.5. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication Segment
  • 9.2. Oncology*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cardiovascular Diseases
  • 9.4. Neurological Diseases
  • 9.5. Renal Disorders
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Research Laboratories
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Validation
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Thermo Fisher Scientific*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bio-Rad Laboratories, Inc.
  • 13.3. Myriad Genetics, Inc.
  • 13.4. QIAGEN
  • 13.5. Eurofins Scientific
  • 13.6. Exact Sciences
  • 13.7. Sema4
  • 13.8. Creative Diagnostics
  • 13.9. Centogene N.V.
  • 13.10. Quanterix

LIST NOT EXHAUSTIVE

14. Global Genomic Biomarker Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us